What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cancer
His main research concerns Internal medicine, Colorectal cancer, Cancer research, Cancer and Genetics.
The various areas that Daniel C. Chung examines in his Internal medicine study include Gastroenterology, Endocrinology and Oncology.
His Oncology research integrates issues from Germline mutation, Carcinoid syndrome, Pathology, Late presentation and Natural history.
In his works, he undertakes multidisciplinary study on Colorectal cancer and Microsatellite instability.
His studies in Cancer research integrate themes in fields like Regulation of gene expression and Loss of heterozygosity.
His Cancer research is multidisciplinary, incorporating elements of Genetic counseling, Genetic testing and Hereditary diffuse gastric cancer.
His most cited work include:
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (1739 citations)
- Gastroenteropancreatic neuroendocrine tumours. (1225 citations)
- Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment (993 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Colorectal cancer, Cancer research, Oncology and Pathology.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology.
His Colorectal cancer research is multidisciplinary, incorporating elements of Bevacizumab, Surgery and Genetic testing.
Daniel C. Chung works mostly in the field of Cancer research, limiting it down to topics relating to Loss of heterozygosity and, in certain cases, Tumor suppressor gene, as a part of the same area of interest.
His research on Oncology frequently connects to adjacent areas such as Germline mutation.
His work in Lynch syndrome addresses subjects such as MLH1, which are connected to disciplines such as MSH6.
He most often published in these fields:
- Internal medicine (29.23%)
- Colorectal cancer (21.86%)
- Cancer research (17.21%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (29.23%)
- Colorectal cancer (21.86%)
- RPE65 (4.64%)
In recent papers he was focusing on the following fields of study:
Daniel C. Chung mainly focuses on Internal medicine, Colorectal cancer, RPE65, Oncology and Ophthalmology.
His research on Internal medicine often connects related areas such as Gastroenterology.
His study in the field of Lynch syndrome also crosses realms of Microsatellite instability.
His RPE65 research incorporates themes from Disease and Mutation.
Daniel C. Chung focuses mostly in the field of Ophthalmology, narrowing it down to topics relating to Phase i ii and, in certain cases, Genetic enhancement.
His Genetics study which covers Natural history that intersects with Gene.
Between 2016 and 2021, his most popular works were:
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial (562 citations)
- NCCN guidelines® insights: Genetic/Familial High-Risk Assessment: Colorectal, version 3.2017 featured updates to the NCCN Guidelines (111 citations)
- Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. (74 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
Colorectal cancer, Internal medicine, Oncology, Cancer and Lynch syndrome are his primary areas of study.
His study in Colorectal cancer is interdisciplinary in nature, drawing from both Risk assessment, Cancer research, DNA methylation, Genome instability and Genetic testing.
His work carried out in the field of Genetic testing brings together such families of science as Genetic counseling, Early onset and Pathology.
The concepts of his Internal medicine study are interwoven with issues in RPE65 and Pediatrics.
As part of his studies on Oncology, Daniel C. Chung often connects relevant areas like Retinal.
His work on Cetuximab as part of his general Cancer study is frequently connected to Cost effectiveness, thereby bridging the divide between different branches of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
